Search

Your search keyword '"Patani, Neill"' showing total 259 results
Start Over Author "Patani, Neill"
259 results on '"Patani, Neill"'

1. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer

Author

Kreuzaler, Peter, Inglese, Paolo, Ghanate, Avinash, Gjelaj, Ersa, Wu, Vincen, Panina, Yulia, Mendez-Lucas, Andres, MacLachlan, Catherine, Patani, Neill, Hubert, Catherine B., Huang, Helen, Greenidge, Gina, Rueda, Oscar M., Taylor, Adam J., Karali, Evdoxia, Kazanc, Emine, Spicer, Amy, Dexter, Alex, Lin, Wei, Thompson, Daria, Silva Dos Santos, Mariana, Calvani, Enrica, Legrave, Nathalie, Ellis, James K., Greenwood, Wendy, Green, Mary, Nye, Emma, Still, Emma, Barry, Simon, Goodwin, Richard J. A., Bruna, Alejandra, Caldas, Carlos, MacRae, James, de Carvalho, Luiz Pedro Sório, Poulogiannis, George, McMahon, Greg, Takats, Zoltan, Bunch, Josephine, and Yuneva, Mariia

Published
2023
Full Text
View/download PDF

2. Pre-operative Radiotherapy And Deep Inferior Epigastric Artery Perforator (DIEP) flAp study (PRADA): Aesthetic outcome and patient satisfaction at one year

Author

Cleator, Susan, Godden, Amy, Gujral, Dorothy, Hadjiminas, Dimitri, James, Stuart E., Khan, Aadil, Kirby, Anna M., Leff, Daniel R., MacNeill, Fiona A., Patani, Neill, Ross, Gillian, Rusby, Jennifer E., Somaiah, Navita, Thiruchelvam, Paul TR, Wood, Simon H, Godden, Amy R., Micha, Aikaterini, O'Connell, Rachel L., Mohammed, Kabir, and Thiruchelvam, Paul T.R.

Published
2023
Full Text
View/download PDF

3. Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study

Author

Thiruchelvam, Paul TR, Leff, Daniel R, Godden, Amy R, Cleator, Susan, Wood, Simon H, Kirby, Anna M, Somaiah, Navita, Patani, Neill, Gujral, Dorothy, Ross, Gillian, James, Stuart, Khan, Aadil, Rusby, Jennifer E, Hadjiminas, Dimitri, MacNeill, Fiona A, Thiruchelvam, Paul T R, Jallali, Navid, Hunter, Judith E, Henry, Francis P, Micha, Aikaterini, O'Connell, Rachel L, Mohammed, Kabir, Tan, Melissa L H, James, Stuart E, Khan, Aadil A, and Hadjiminas, Dimitri J

Published
2022
Full Text
View/download PDF

4. Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship

Author

Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Sangiorgio, Valentina F.I., Ruiz-Cordero, Roberto, Vega, Francisco, Feldman, Andrew L., Chapman, Jennifer R., Clemens, Mark W., Hunt, Kelly K., Evans, Mark G., Khoo, Christine, Lade, Stephen, Silberman, Mark, Morkowski, Jerzy, Pina, Edward M., Mills, Daniel C., Bates, Christopher M., Magno, Winston B., Sohani, Aliyah R., Sieling, Beth A., O'Donoghue, Joseph M., Bacon, Chris M., Patani, Neill, Televantou, Despina, Turner, Suzanne D., Johnson, Laura, MacNeill, Fiona, Wotherspoon, Andrew C., Iyer, Swaminathan P., Malpica, Luis E., Patel, Keyur P., Xu, Jie, and Miranda, Roberto N.

Published
2021
Full Text
View/download PDF

7. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: protocol for a prospective, multicentre cohort study

Author

Hartup, Sue M., primary, Morgan, Jenna L., additional, Cheng, Vinton WT, additional, Barry, Peter A., additional, Copson, Ellen, additional, Cutress, Ramsey I., additional, Dave, Rajiv, additional, Elsberger, Beatrix, additional, Fairbrother, Patricia, additional, Hogan, Brian, additional, Horgan, Kieran, additional, Kirwan, Cliona C., additional, McIntosh, Stuart A., additional, O’Connell, Rachel L., additional, Patani, Neill, additional, Potter, Shelley, additional, Rattay, Tim, additional, Sheehan, Lisa, additional, Wyld, Lynda, additional, and Kim, Baek, additional

Published
2024
Full Text
View/download PDF

8. Wire-Free Targeted Axillary Dissection: A Pooled Analysis of 1300+ Cases Post-Neoadjuvant Systemic Therapy in Node-Positive Early Breast Cancer.

Author

Varghese, Jajini, Patani, Neill, Wazir, Umar, Novintan, Shonnelly, Michell, Michael J., Malhotra, Anmol, Mokbel, Kinan, and Mokbel, Kefah

Subjects
*SENTINEL lymph node biopsy, *PATIENT safety, *BREAST tumors, *AXILLARY lymph node dissection, *PATHOLOGIC complete response, *CHI-squared test, *DESCRIPTIVE statistics, *CANCER patients, *SYSTEMATIC reviews, *MEDLINE, *COMBINED modality therapy, *QUALITY of life, *ONLINE information services, *CONFIDENCE intervals, *DATA analysis software, *DISEASE incidence, *OVERALL survival
Abstract

Simple Summary: Preoperative chemotherapy significantly improves response rates in early breast cancer, challenging the traditional approach of invasive axillary surgery in patients presenting with node-positive disease. Wire-free localisation markers can successfully mark lymph nodes at diagnosis. Our findings demonstrate that these markers are successfully utilised, localised, and retrieved intraoperatively. Incorporating preoperative lymph node marking into the current biopsy procedure allows for more accurate staging of the axilla whilst reducing the need for invasive axillary surgery. These findings underscore the importance of incorporating both types of biopsies in axillary staging following preoperative chemotherapy for initially node-positive patients. Recent advances in neoadjuvant systemic therapy (NST) have significantly improved pathologic complete response rates in early breast cancer, challenging the role of axillary lymph node dissection in nose-positive patients. Targeted axillary dissection (TAD) integrates marked lymph node biopsy (MLNB) and tracer-guided sentinel lymph node biopsy (SLNB). The introduction of new wire-free localisation markers (LMs) has streamlined TAD and increased its adoption. The primary endpoints include the successful localisation and retrieval rates of LMs. The secondary endpoints include the pathological complete response (pCR), SLNB, and MLNB concordance, as well as false-negative rates. Seventeen studies encompassing 1358 TAD procedures in 1355 met the inclusion criteria. The localisation and retrieval rate of LMs were 97% and 99%. A concordance rate of 67% (95% CI: 64–70) between SLNB and MLNB was demonstrated. Notably, 49 days (range: 0–272) was the average LM deployment time to surgery. pCR was observed in 46% (95% CI: 43–49) of cases, with no significant procedure-related complications. Omitting MLNB or SLNB would have under-staged the axilla in 15.2% or 5.4% (p = 0.0001) of cases, respectively. MLNB inclusion in axillary staging post-NST for initially node-positive patients is crucial. The radiation-free Savi Scout, with its minimal MRI artefacts, is the preferred technology for TAD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship.” [Modern Pathology 34 (2021) 2154–2167]

Author

Medeiros, L. Jeffrey, primary, Marques-Piubelli, Mario L., additional, Sangiorgio, Valentina F.I., additional, Ruiz-Cordero, Roberto, additional, Vega, Francisco, additional, Feldman, Andrew L., additional, Chapman, Jennifer R., additional, Clemens, Mark W., additional, Hunt, Kelly K., additional, Evans, Mark G., additional, Khoo, Christine, additional, Lade, Stephen, additional, Silberman, Mark, additional, Morkowski, Jerzy, additional, Pina, Edward M., additional, Mills, Daniel C., additional, Bates, Christopher M., additional, Magno, Winston B., additional, Sohani, Aliyah R., additional, Sieling, Beth A., additional, O’Donoghue, Joseph M., additional, Bacon, Chris M., additional, Patani, Neill, additional, Televantou, Despina, additional, Turner, Suzanne D., additional, Johnson, Laura, additional, MacNeill, Fiona, additional, Wotherspoon, Andrew C., additional, Iyer, Swaminathan P., additional, Malpica, Luis E., additional, Patel, Keyur P., additional, Xu, Jie, additional, and Miranda, Roberto N., additional

Published
2023
Full Text
View/download PDF

11. Reevaluating Axillary Lymph Node Dissection in Total Mastectomy for Low Axillary Burden Breast Cancer: Insights from a Meta-Analysis including the SINODAR-ONE Trial.

Author

Alamoodi, Munaser, Patani, Neill, Mokbel, Kinan, Wazir, Umar, and Mokbel, Kefah

Subjects
*ONLINE information services, *META-analysis, *SYSTEMATIC reviews, *RESEARCH funding, *MASTECTOMY, *LUMPECTOMY, *SENTINEL lymph nodes, *MEDLINE, *AXILLARY lymph node dissection, *BREAST tumors, *OVERALL survival
Abstract

Simple Summary: In the past, breast cancer patients with lymph node involvement often had surgery to remove most or all of the lymph nodes in the armpit, which can cause significant side effects. However, recent research, like the ACOSOG Z0011 study, has shown that for patients with only a few affected lymph nodes who are getting breast-conserving treatment and radiation treatment, this extensive surgery might not be necessary and doesn't affect their chances of survival. This study looked at whether the same applies to patients having a total mastectomy. We analyzed several studies involving over 4000 patients and found that skipping the extensive lymph node surgery didn't impact overall survival after about 7 years of follow-up. This suggests that certain breast cancer patients having mastectomy with limited lymph node involvement, can safely avoid the more invasive surgery for the lymph nodes in armpit. However, more research is needed to fully understand how other factors might affect survival. Complete axillary lymph node dissection (cALND) was previously the standard of care for breast cancer (BC) patients with axillary node disease or macro-metastases found via sentinel lymph node biopsy (SLNB). However, due to significant morbidity, contemporary management now considers a more selective approach, influenced by studies like ACOSOG Z0011. This trial showed that cALND could be omitted without compromising local control or survival in patients with low axillary nodal disease burden undergoing breast-conserving therapy, radiotherapy, and systemic therapy. The relevance of this approach for women with low axillary nodal burden undergoing total mastectomy (TM) remained unclear. A PubMed search up to September 2023 identified 147 relevant studies, with 6 meeting the inclusion criteria, involving 4184 patients with BC and low-volume axillary disease (1–3 positive lymph nodes) undergoing TM. Postmastectomy radiotherapy receipt was similar in both groups. After a mean 7.2-year follow-up, both the pooled results and the meta-analysis revealed no significant differences in overall survival. The combined analysis of the published studies, including the subgroup analysis of the SINODAR-One trial, indicates no survival advantage for cALND over SLNB in T1–T2 breast cancer patients with 1–3 positive sentinel lymph nodes (pN1) undergoing mastectomy. This suggests that, following a multidisciplinary evaluation, cALND can be safely omitted. However, the impact of other patient, tumor, and treatment factors on survival requires consideration and therefore further prospective trials are needed for conclusive validation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Mastitis and Mammary Abscess Management Audit (MAMMA) in the UK and Ireland.

Author

Courtney, Alona, Clymo, Jonathon, Parks, Ruth, Wilkins, Alexander, Brown, Ruth, O'Connell, Rachel, Dave, Rajiv, Dillon, Marianne, Fatayer, Hiba, Gallimore, Rachel, Gandhi, Ashu, Gardiner, Matthew, Harmer, Victoria, Hookway, Lyndsey, Irwin, Gareth, Ives, Charlotte, Mathers, Helen, Murray, Juliette, O'Leary, D Peter, and Patani, Neill

Subjects
MASTITIS, ABSCESSES, SURGICAL site, SURGICAL drainage, HOSPITAL patients, NEEDLE biopsy, NEEDLES & pins, NEEDLESTICK injuries
Abstract

Background: The aim of this multicentre prospective audit was to describe the current practice in the management of mastitis and breast abscesses in the UK and Ireland, with a specific focus on rates of surgical intervention. Methods: This audit was conducted in two phases from August 2020 to August 2021; a phase 1 practice survey and a phase 2 prospective audit. Primary outcome measurements for phase 2 included patient management pathway characteristics and treatment type (medical/radiological/surgical). Results: A total of 69 hospitals participated in phase 2 (1312 patients). The key findings were a high overall rate of incision and drainage (21.0 per cent) and a lower than anticipated proportion of ultrasound-guided aspiration of breast abscesses (61.0 per cent). Significant variations were observed regarding the rate of incision and drainage (range 0–100 per cent; P < 0.001) and the rate of needle aspiration (range 12.5–100 per cent; P < 0.001) between individual units. Overall, 22.5 per cent of patients were admitted for inpatient treatment, out of whom which 72.9 per cent were commenced on intravenous antibiotics. The odds of undergoing incision and drainage for a breast abscess or being admitted for inpatient treatment were significantly higher if patients presented at the weekend compared with a weekday (P ≤ 0.023). Breast specialists reviewed 40.9 per cent of all patients directly, despite the majority of patients (74.2 per cent) presenting within working hours on weekdays. Conclusions: Variation in practice exists in the management of mastitis and breast abscesses, with high rates of incision and drainage in certain regions of the UK. There is an urgent need for a national best-practice toolbox to minimize practice variation and standardize patient care. The Mastitis and Mammary Abscess Management Audit (MAMMA) is the first international audit, conducted in 69 hospitals across the UK and Ireland, involving contemporaneous data capture on the presentation and management of 1312 patients with mastitis and breast abscess. Key results included a substantial inpatient admission rate (22.5 per cent), a high overall rate of surgical incision and drainage (21.0 per cent), and a comparatively low use of ultrasound-guided aspiration (61.0 per cent). The data also identified significantly increased odds of undergoing incision and drainage for a breast abscess or being admitted for inpatient treatment, if patients presented at the weekend compared with on a weekday. Lay Summary: Mastitis and breast abscess is a painful infection of the breast. It is an extremely common breast problem. One in three women can get this condition at some stage in their life. To treat a breast abscess, the pus inside should be drained out of the body. This can be done either by cutting into the breast using surgery or by inserting a fine needle using an ultrasonography scan (which uses ultrasound). Fine-needle drainage has the benefit that it does not require admission to hospital. Surgery can cause the breast to look misshapen. It is unknown which method is used more often in the UK and Ireland. The aim of this study was to describe how mastitis and breast abscesses are treated in the UK and Ireland. This study involved a survey of practice (phase 1) and collection of data, which are routinely recorded for these patients (phase 2). This study involved 69 hospitals and 1312 patient records. One in five women had an operation for a breast abscess. This was higher than expected. Six in 10 women had a pus drainage using a fine needle. The chance of having an operation depended on the hospital. Women that came to hospital at the weekend were almost twice as likely to have an operation. One in five women were admitted to hospital. The chances of that more than doubled if a woman came to hospital at the weekend. There are differences in treatment of mastitis and breast abscesses across the UK and Ireland. Changes need to be put in place to make access to treatment more equal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Supplementary Table 2 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Tables 7 - 8 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figures 1 - 3 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends, Table Legends from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables 3 - 6 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Tables 11 - 13 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 9 - 10 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Author

Patani, Neill, primary, Dunbier, Anita K., primary, Anderson, Helen, primary, Ghazoui, Zara, primary, Ribas, Ricardo, primary, Anderson, Elizabeth, primary, Gao, Qiong, primary, A'hern, Roger, primary, Mackay, Alan, primary, Lindemann, Justin, primary, Wellings, Robert, primary, Walker, Jill, primary, Kuter, Irene, primary, Martin, Lesley-Ann, primary, and Dowsett, Mitch, primary

Published
2023
Full Text
View/download PDF

25. Discovery of multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer

Author

Menegollo, Michela, primary, Bentham, Robert B., additional, Henriques, Tiago, additional, Ng, Seow Qi, additional, Ren, Ziyu, additional, Esculier, Clarinde, additional, Agarwal, Sia, additional, Tong, Emily, additional, Lo, Clement, additional, Ilangovan, Sanjana, additional, Szabadkai, Zorka, additional, Suman, Matteo, additional, Patani, Neill, additional, Ghanate, Avinash, additional, Bryson, Kevin, additional, Stein, Robert C., additional, Yuneva, Mariia, additional, and Szabadkai, Gyorgy, additional

Published
2023
Full Text
View/download PDF

27. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision making

Author

Morgan, Jenna L., primary, Cheng, Vinton, additional, Barry, Peter A., additional, Copson, Ellen, additional, Cutress, Ramsey I., additional, Dave, Rajiv, additional, Elsberger, Beatrix, additional, Fairbrother, Patricia, additional, Hartup, Sue, additional, Hogan, Brian, additional, Horgan, Kieran, additional, Kirwan, Cliona C., additional, McIntosh, Stuart A., additional, O'Connell, Rachel L., additional, Patani, Neill, additional, Potter, Shelley, additional, Rattay, Tim, additional, Sheehan, Lisa, additional, Wyld, Lynda, additional, and Kim, Baek, additional

Published
2022
Full Text
View/download PDF

29. MAMMA (Mastitis And Mammary Abscess Management Audit): Phase 2 outcomes

Author

Courtney, Alona, primary, Parks, Ruth, additional, Wilkins, Alexander, additional, Brown, Ruth, additional, O'Connell, Rachel, additional, Dave, Rajiv, additional, Dillon, Marianne, additional, Fatayer, Hiba, additional, Gallimore, Rachel, additional, Gandhi, Ashu, additional, Gardiner, Matthew, additional, Harmer, Victoria, additional, Hookway, Lyndsey, additional, Irwin, Gareth, additional, Ives, Charlotte, additional, Mathers, Helen, additional, Murray, Juliette, additional, O’Leary, Peter, additional, Patani, Neill, additional, Paterson, Sophie, additional, Potter, Shelley, additional, Prichard, Ruth, additional, Satta, Giovanni, additional, Teoh, T.G., additional, Ziprin, Paul, additional, and Leff, Daniel R., additional

Published
2022
Full Text
View/download PDF

31. The Impact of COVID-19 on Clinical Nurse Specialists and Patients With Cancer:A Pan-Specialty Cross-sectional Survey

Author

Forster, Alice S, Zylstra, Janine, von Wagner, Christian, Hirst, Yasemin, Forster, Martin, Walshe, Rebecca, Kazzaz, Zainab, Steptoe, Andrew, Birchall, Martin, Patani, Neill, Forster, Alice S, Zylstra, Janine, von Wagner, Christian, Hirst, Yasemin, Forster, Martin, Walshe, Rebecca, Kazzaz, Zainab, Steptoe, Andrew, Birchall, Martin, and Patani, Neill

Abstract

PURPOSE/AIMS: Uptake and delivery of cancer services across the United Kingdom have been significantly impacted by the COVID-19 pandemic. This study aimed to understand the impact of the pandemic on the working practices of clinical nurse specialists and their patient interactions across different cancer specialties. DESIGN: We performed a cross-sectional survey exploring nurses' experiences of delivering care during the pandemic, as well as their perceptions of the concerns that cancer patients were experiencing. METHODS: Clinical nurse specialists working in London cancer services were invited to complete an online questionnaire. Nurses' experiences and their perceptions of patients' concerns were analyzed descriptively. RESULTS: Fifty-four nurses participated. Almost half had been redeployed to other clinical areas during the pandemic (n = 19). COVID-19 discussions added 5 to 10 minutes on average to most consultations, with nurses either working longer/unpaid hours (34%) or spending less time talking to patients about cancer (39%) to deal with this. Approximately 50% of nurses would have liked additional information and support from their hospital. CONCLUSIONS: Clinical nurse specialist time and resources have been stretched during the COVID-19 pandemic. Hospitals need to work with nursing staff to ensure the specific information needs of cancer patients are being met.

Published
2022

36. Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.

Author

Wazir, Umar, Patani, Neill, Balalaa, Nahed, and Mokbel, Kefah

Subjects
*CONSERVATIVE treatment, *CONFIDENCE intervals, *SYSTEMATIC reviews, *CANCER invasiveness, *DUCTAL carcinoma, *COMBINED modality therapy, *MEDLINE, *MASTECTOMY, *CARCINOMA in situ, *BREAST tumors
Abstract

Simple Summary: Traditionally, the presence of ductal carcinoma in situ (DCIS) with invasive breast cancer meant that the patient may require complete removal of the breast in order to completely remove the disease. Recently there has been some evidence to the contrary. In this article, we have reviewed the current published literature to determine the rate at which DCIS was eradicated by chemotherapy and endocrine therapies administered prior to surgery, which we determined to be 40.5% and 15% respectively. This suggests that in patient who respond well to pre-surgical systemic therapy, breast conserving surgery (BCS) could be offered. This should lessen patient anxiety and morbidity. Contrary to traditional assumptions, recent evidence suggests that neoadjuvant systemic therapy (NST) given for invasive breast cancer may eradicate co-existent ductal carcinoma in-situ (DCIS), which may facilitate de-escalation of breast resections. The aim of this systematic review was to assess the eradication rate of DCIS by NST given for invasive breast cancer. Searches were performed in MEDLINE using appropriate search terms. Six studies (N = 659) in which pathological data were available regarding the presence of DCIS prior to neoadjuvant chemotherapy (NACT) were identified. Only one study investigating the impact of neoadjuvant endocrine therapy (NET) met the search criteria. After pooled analysis, post-NACT pathology showed no residual DCIS in 40.5% of patients (267/659; 95% CI: 36.8–44.3). There was no significant difference in DCIS eradication rate between triple negative breast cancer (TNBC) and HER2-positive disease (45% vs. 46% respectively). NET achieved eradication of DCIS in 15% of patients (9/59). Importantly, residual widespread micro-calcifications after NST did not necessarily indicate residual disease. In view of the results of the pooled analysis, the presence of extensive DCIS prior to NST should not mandate mastectomy and de-escalation to breast conserving surgery (BCS) should be considered in patients identified by contrast enhanced magnetic resonance imaging (CE-MRI). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Author

Dave, Rajiv V., Kim, Baek, Courtney, Alona, O’Connell, Rachel, Rattay, Tim, Taxiarchi, Vicky P., Kirkham, Jamie J., Camacho, Elizabeth M., Fairbrother, Patricia, Sharma, Nisha, Cartlidge, Christopher W. J., Horgan, Kieran, McIntosh, Stuart A., Leff, Daniel R., Vidya, Raghavan, Holcombe, Chris, Copson, Ellen, Coles, Charlotte E., Cutress, Ramsey I., Gandhi, Ashu, Kirwan, Cliona C., Agrawal, Amit, Benson, John, Forouhi, Parto, Wignarajah, Primeera, Shrotri, Anu, Kattakayam, Arjun, Noronha, Jarin Louis, Martin, Lee, Lafi, Mohamed, Hardy, Rob, Amin, Khalid, AL-Zawi, Abdalla Saad Abdalla, Elamass, Mohamed, Salih, Ali, Alkistawi, Firas Eddin Bachir, Heeney, Anna, Hill, Arnold D. K., Power, Colm, Allen, Michael J., Chouhan, Ashok, Rathinaezhil, Rathi, Shaheed, Samy, Zammit, Charles, Clayton, Gillian, Dua, Sascha, Smith, Simon, Gandamihardja, Tasha, Williams, Chloe, Egbeare, Donna, Davies, Eleri, Sweetland, Helen M., Chopra, Sharat, Goyal, Sumit, Elfadl, Dalia, Rana, Dheer Singh, Kalakouti, Eliana, Barkeji, Musa, Vashisht, Rajiv, Bunza, Ralia, Phyu, Saung Hnin, Hollywood, Ciaran, Azmy, Iman, Massey, Julia, Hargreaves, Anita, Harding-Mackean, Claudia, Ooi, Jane, Seward, Joanna, Mathers, Helen, Scally, Norah, Salman, Reem, Shin, Hyunjin, Turner, Jane, Noor, Lubna, Joshi, Sanjay, Horne, Sarah, Sarakbi, Wail Al, Liptay-Wagner, Peter, Jacklin, Rosamond, Chandrasekharan, Sankaran, Marsh, Simon, Saha, Sunita, Wilson, Christopher, Rutherford, Claire Louise, Doughty, Julie, Romics, Laszlo, Stallard, Sheila, Chaudhry, Anushka, Peck, Jennifer, Coombs, Nathan, Williams, Samantha K., Hawkins, Simon, Kothari, Ashutosh, Hamed, Hisham, Jain, Urvashi, Daltrey, Ian, Abbott, Nick, Mullen, Russell, Dumitru, Dorin, Khalifa, Eiman, Sarker, Masuma, Elahi, M. Bilal, Bichoo, Raouef Ahmed, Gvaramadze, Anzors, Thekkinkattil, Dinesh, Jibril, Jibril, Hadjiminas, Demetrios, St John, Edward R. C., Robb, Henry Douglas, Hogben, Katy, Bakri, Nur Amalina Che, Thiruchelvam, Paul, Exarchos, Georgios, Al-Mufti, Ragheed, Mortimer, Caroline, Mallidis, Evangelos, Karagiannidis, Georgios, Tuffaha, Hussein, Peerlink, Inga, Nair, Rajive, Prusty, Lydia, Sami, Amtul, Knight, Alex, Ravichandran, Duraisamy, Kirkpatrick, Katharine, James, Ruth, Akolekar, Deepika, Mehta, Disha, Barua, Ellora, Knowles, Hannah, Devalia, Haresh, Cox, Karina, Dani, Mohsin, Chalmers, Ritchie, Satpathy, Anjana, Quinn, Edel, Byrne, Gerard, Harvey, James, Murphy, John, Highton, Lyndsey, Sharif, Mohammad Amir, Barnes, Nicola, Dimopoulos, Nikitas, Johnson, Richard, Chatterjee, Sumohan, Fatayer, Hiba, Mathen, Vinod, Taylor, Amanda, Soulsby, Rachel, Walsh, Adam, Thorne, Amanda, Gill, Jasper, Merker, Louise, Critchley, Adam, Pieri, Andrew, Cain, Henry, Ralph, Jane, Kalra, Loraine, Thomas, Robert, Young, Ian, Khan, Lucy R., Elsberger, Beatrix, Smyth, Elizabeth, Urquhart, Gordon, Fuller, Mairi, Masannat, Yazan, Chrysafi, Ada, Salman, Muhammad, Abdalla, El-Rasheed, Zechmeister, Katalin, Hussien, Maged, Youssef, Mina M. G., Tanhueco, Angeline, Salvador, Reginald, Wallace, Sharon, Pain, Simon, Sahu, Ajay, Chambers, Alice, Moody, Alice, Dash, Isabella, Cook, James, Batt, Jeremy, Mullan, Michelle, Shere, Mike, Gallegos, Nicholas, Ainsworth, Rachel, Govindarajulu, Sasi, Potter, Shelley, Rayter, Zenon, Williams, Kate E., Bramley, Maria, Absar, Mohammed, Nasir, Nabila, Tabbakh, Rami, Pereira, Bernadette, Gahir, Jasdeep, Bosch, Karen, Fafemi, Oladapo, Touqan, Nader, Oni, Georgette, Khout, Hazem, Asgeirsson, Kristjan, Whisker, Lisa, Lee, Rachel Xue Ning, Macmillan, Robert, McCulley, Stephen, Rasheed, Tuabin, Adwani, Asha, Segaran, Ashvina, Dodwell, David, Remoundos, Dennis, MacLean, Gael, Cuffolo, Giulio, Douek, Michael, Roy, Pankaj, Gathani, Toral, Najeeb, Erum, Simonca, Claudiu, Verroiotou, Maria, Ramzi, Sa’ed, Jenkins, Stephanie C., Gopalan, Vallipuran, Barker, Sarah, McGoldrick, Ciara, Irwin, Gareth W., Mallon, Peter, Sloan, Samantha A., Imran, Abbas, Mondani, Giuseppina, Brown, Iain, Abbas, Imran, Sulieman, Mona, Drew, Philip, King, Polly, English, Rachel Elizabeth, Sharma, Anita, Ives, Charlotte, Ferguson, Douglas, Boundouki, George, Bentley, James, Banks, Jenny, Dunn, Julie, Tillett, Rachel, Olsen, Sisse, Tansley, Anne, Sousa, Emma De, Mitchell, Geraldine, Whitehead, Ian, Henderson, Julia, Rowland, Matthew, Chandrashekar, Mysore, Eid, Raja, Clayton, Elizabeth, Pakzad, Farrokh, Horsnell, Jonathan D., Hague, Matthew, Partlett, Polly, Irvine, Tracey, Kallaway, Charlotte, Fairhurst, Katherine, Laban, Christiana, McIntosh, Jamie, Laurence, Nicola, Sutton, Richard, Sharma, Anup, Banerjee, Dibyesh, Betambeau, Nadine, Bezzaa, Sabrina, Bathla, Sonia, Ray, Atanu, Chagla, Leena, Kiernan, Tamara, Hogan, Brian, Navin, Channegowda, Macinnes, Emma, Turton, Philip, Achuthan, Raj, Kantola, Venla, Mckenzie, Shireen, Dent, Helen, Pogson, Caroline, Waheed, Shamaela, De Silva, Tania S., Suleiman, Usama, Jones, Lucie, Athwal, Ruvinder, Harries, Simon, Krzyzanowska, Catherine, Abbas, Abeera, Hurley, Anna R., Gui, Gerald, Rusby, Jennifer E., Krupa, Katherine, Harborough, Kathryn E., Roche, Nicola, Barry, Peter A., Law, Rebekah, Allum, William H., Lobo, Cheryl, Ntakomyti, Eleni, Franks, Joanna, Cariati, Massimiliano, Patani, Neill, Stanilov, Noyko, Charalampoudis, Petros, Taraki, Zarghuna, McEvoy, Kat, Sait, Mohamed Razick, Robertson, Stuart, Zeidan, Bashar, Rew, David, Mazari, Fayyaz, Alder, Louise, Sakellariou, Vasileios, Hamad, Ahmed, Goyal, Amit, Carmichael, Amtul, Courtney, Carol-Ann, Sibbering, David Mark, Garreffa, Emanuele, Cheung, Kwok-Leung, Williams-Jones, Susan, Wahedna, Yasmin, Ansari, Aonghus, Kenny, Frances, Valassiadou, Kalliope, Lambert, Kelly, Krupa, Jaroslaw, Sardar, Mini V., Kaushik, Monika, Shokuhi, Sheila, Pilgrm, Simon, Sasi, Walid, McManus, Penelope, Parmeshwar, Rishikesh, Somasundaram, Santosh, Gowda, Manoj, Jafferbhoy, Sadaf, Narayanan, Sankaran, Marla, Sekhar, Soumian, Soni, Goh, Ngee-Ming, Vatish, Jamie, Sein, Tin Aung, Agabiti, Ennio, Maalo, Joseph, Chong, Kelvin, Lai, Lee-Min, Elkorety, Mohamed, Monib, Sherif, Thomson, Simon, Mikhael, Youhana, Mirshekar-Syahkal, Bahar, Aitken, Jane, Girgis, Mina, Betal, Dibendu, Rapisarda, Fabio, Cook, Lorna, Odofin, Olubunmi, Bonomi, Riccardo, Wardle, Stacy, Sotheran, Wendy, Athanasiou, Irene, Lund, Jonathan, Callaghan, Maria, Burrah, Rajaram, Vinayagam, Raman, James, Karen, Poonawala, Shabbir, Isgar, Brian, Matey, Pilar, Mylvaganam, Senthurun, Podesta, Carl, Sircar, Tapan, Salem, Fathi, Al-Ishaq, Zaid, Dave, Rajiv V. [0000-0001-6827-8090], McIntosh, Stuart A. [0000-0002-4123-9611], Potter, Shelley [0000-0002-6977-312X], Copson, Ellen [0000-0001-8994-4056], and Apollo - University of Cambridge Repository

Subjects
692/700/784, article, 692/4028/67/1347, 692/700/3934, 692/700/1538, 692/4028/546
Abstract

Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.

Published
2021
Full Text
View/download PDF

45. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

Author

Whitehead, I., Irwin, G. W., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., Irshad, S., O’Brien, C., O’Connell, R. L., Palmieri, C., Shaaban, A. M., Sharma, N., Singh, J. K., Potter, S., McIntosh, S. A., Clayton, Liz, Copson, Ellen, Cox, Karina, Crook, Tim, Elsberger, Beatrix, Ghoneima, Ahmed, Hadad, Sirwan, Hargreaves, Anita, Healy, Paul, Heetun, Adam, Henderson, Dan, Henderson, Julia, Hirst, Natalie, Hoar, Fiona, Hughes, Mike, Iddles, Emma, Irshad, Sheeba, Irvine, Tracey, Jones, Stacey, Kaptanis, Sarantos, MacInnes, Emma, McCanny, Andrew, McLaughlin, Linda, Neal, Anthony, O’Connell, Rachel, Patani, Neill, Pearce, Belinda, Pennick, Mandana, Pilgrim, Simon, Roux, Rene, Rowland, Matthew, Saha, Sunita, Sharma, Kavita, Singh, Jagdeep, Sirianni, Chiara, Skelly, Brendan, Soulsby, Rachel, Tatterton, Mark, Thomas, Rob, Tsalic, Medy, Vidya, Raghavan, Waker, Olivia, Whisker, Lisa, Whitehead, Ian, Woods, Janet, and Apollo - University of Cambridge Repository

Subjects
Endocrine therapy, Neoadjuvant treatment, Breast cancer, Chemotherapy, Surgery, Research Article, Surgical oncology, cancer imaging, and interventional therapeutics
Abstract

Background: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment response, and post-treatment surgical management. Methods: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017 and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item. Results: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant chemotherapy (NACT) to a median of 10% (range 5–60%) of patients. Neoadjuvant endocrine therapy (NET) was offered to a median of 4% (range 0–25%) of patients by 66% of MDTs. The principal indication given for use of neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response. Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB) in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would receive axillary node clearance at 60% of centres, regardless of response to NACT. Discussion: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and clinical outcomes.

Published
2021
Full Text
View/download PDF

46. Additional file 3 of Intraoperative [18F]FDG flexible autoradiography for tumour margin assessment in breast-conserving surgery: a first-in-human multicentre feasibility study

Author

Jurrius, Patriek A. G. T., Grootendorst, Maarten R., Krotewicz, Marika, Cariati, Massimiliano, Kothari, Ashutosh, Patani, Neill, Karcz, Paulina, Nagadowska, Monika, Vyas, Kunal N., Purushotham, Arnie, and Turska-D’Amico, Maria

Abstract

Additional file 3: Table 2. Confusion matrix of FAR imaging for intraoperative margin assessment of intact WLE specimens compared to gold standard histopathology. The patients were divided into three subgroups based on T-classification.

Published
2021
Full Text
View/download PDF

47. Additional file 2 of Intraoperative [18F]FDG flexible autoradiography for tumour margin assessment in breast-conserving surgery: a first-in-human multicentre feasibility study

Author

Jurrius, Patriek A. G. T., Grootendorst, Maarten R., Krotewicz, Marika, Cariati, Massimiliano, Kothari, Ashutosh, Patani, Neill, Karcz, Paulina, Nagadowska, Monika, Vyas, Kunal N., Purushotham, Arnie, and Turska-D’Amico, Maria

Abstract

Additional file 2: Table 1. Confusion matrix of FAR imaging for intraoperative margin assessment of intact WLE specimens compared to gold standard histopathology. The patients were divided into two subgroups based on the time between [18F]FDG injection and intraoperative FAR imaging (threshold: 158 min). The mean injection to imaging times between the two subgroups was not statistically significant (p

Published
2021
Full Text
View/download PDF

50. P102. Reporting and management of close/involved anterior margins after skin/nipple-sparing mastectomy: Multi-centre experience of national oncoplastic fellows in England

Author

Rizki, Hirah, primary, Quinn, Edel, additional, Arthur, Laura, additional, Rajan, SreeKumar, additional, Shah, Reena, additional, Goburdhun, Rachna, additional, Tan, Qing, additional, Layton, Abbie, additional, Covington, April, additional, Varghese, Jajini, additional, St John, Edward, additional, Leff, Daniel, additional, and Patani, Neill, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results